通用名药物
參考文獻

↑  藥學名詞. . 樂詞網. 國家教育研究院.   [2022-12-04]. （原始内容存档于2022-12-04）.
↑  , Center for Drug Evaluation and Research, U.S. Food and Drug Administration, 2017-10-06  [2017-11-11], （原始内容存档于2019-04-23）
1 2  . Scientific American.   [2017-11-11]. （原始内容存档于2021-03-03）.
↑  . 术语在线. 全国科学技术名词审定委员会.  （简体中文）
↑  Alan Galbraith, Shane Bullock, Elizabeth Manias, Barry Hunt, Ann Richards.  2. Routledge. 2015: 12. ISBN 9781317325871.
↑  Mary Kamienski, Jim Keogh. . McGraw Hill Professional. 2006: 6. ISBN 9780071483445.
↑  http://zgys.cnjournals.org/html/2018/4/20180413.html
↑  https://www.ccfdie.org/zryyxxw/cfdazsjg/gjydwyh/webinfo/2017/01/1485614811879567.htm
↑  . Food and Drug Administration. January 12, 2010  [2010-02-03]. （原始内容存档于2019-04-23）.
↑  U.S. Food and Drug Administration. . www.fda.gov.   [5 May 2018]. （原始内容存档于2019-04-23） （英语）.
↑  美國法典第35编（英语：） § 第154(a)(2)節
↑   (PDF).   [2020-10-21]. （原始内容存档 (PDF)于2019-04-26）.
1 2 3  . Los Angeles Times. March 25, 2013  [2020-10-21]. （原始内容存档于2015-06-18）.
1 2   (PDF). Washington, DC: Generic Pharmaceutical Association (GPhA). 2015  [16 June 2016]. （原始内容存档 (PDF)于2021-02-24）.
↑  . FDA. Food and drug administration.   [21 May 2018]. （原始内容存档于2019-04-23）.
↑  .   [2020-10-21]. （原始内容存档于2021-03-01）.
↑  . Pharmacy Times. 1 October 2008  [21 May 2018]. （原始内容存档于2021-01-26）.
↑  . Seeking Alpha. Seeking alpha. 2010-10-31  [21 May 2018]. （原始内容存档于2020-07-31）.
1 2  Gupta, H; Kumar, S; Roy, SK; Gaud, RS. . Journal of Pharmacy & Bioallied Sciences. January 2010, 2 (1): 2–7. PMC 3146086 . PMID 21814422. doi:10.4103/0975-7406.62694.
↑  Frakt, Austin. . The New York Times. 28 September 2015  [2020-10-21]. （原始内容存档于2020-11-08）.
↑  DiMasi J.A.;  et al.  (PDF). Journal of Health Economics. 2003, 22 (2): 151–185  [2020-10-21]. PMID 12606142. doi:10.1016/s0167-6296(02)00126-1. hdl:10161/6706. （原始内容存档 (PDF)于2021-02-04）.
↑  Tufts Center for the Study of Drug Development. . Tufts University. November 18, 2014  [2015-12-01]. （原始内容存档于2014-11-21）.
↑  Sabatini, Marco T.; Silva, Miguel. . Pharmaceutical Medicine. 2020-08-09, 34 (4): 271–278. ISSN 1179-1993. PMID 32772314. S2CID 221071039. doi:10.1007/s40290-020-00348-7 （英语）.
↑  . Generic Pharmaceutical Association (GPhA). 2008  [2008-06-16]. （原始内容存档于2008-05-29）.
1 2 3  . Food and Drug Administration. April 2004  [2008-07-11]. （原始内容存档于2008-02-23）.
↑  . www.clihouston.com.   [23 May 2017]. （原始内容存档于2020-10-18）.
↑  Benson, Mike. . Market Realist. February 20, 2015  [2020-10-21]. （原始内容存档于2021-02-02）.
↑  . Forbes. 2007-08-22  [2008-10-13]. []
↑  . Bussiness Wire. February 20, 2008  [21 October 2020]. （原始内容存档于2020-10-24）.
↑  Dasgupta, Neha; Miglani, Sanjeev. . Reuters. 12 July 2018  [12 April 2020]. （原始内容存档于2021-01-24） （英语）.
↑  . 6 March 2020. （原始内容存档于2021-02-12）.
↑  . PharmaPhorum. 4 Apr 2012  [2020-10-21]. （原始内容存档于2013-01-31）.
↑   (PDF). Generics Bulletin. 8 Sep 2006: 10  [2020-10-21]. （原始内容存档 (PDF)于2016-09-09）.
↑  . Health Service Journal. 26 September 2018  [4 November 2018]. （原始内容存档于2020-10-22）.
1 2  Boehm, Garth; Yao, Lixin; Han, Liang; Zheng, Qiang. . Acta Pharmaceutica Sinica B. September 2013, 3 (5): 297–311. doi:10.1016/j.apsb.2013.07.004 .
↑  Altstedter, Ari. . Live Mint. 18 May 2017  [2020-10-21]. （原始内容存档于2020-10-30）.
↑  WHO Technical Report Series No. 937: Annex 7 (pdf) WHO Expert Committee on Specifications for Pharmaceutical Preparations, Fortieth Report (WHO Technical Report Series No. 937): Annex 7 – Multisource (generic) pharmaceutical products: guidelines on registration requirements to establish interchangeability, May 2006. Accessed 2008-06-15
↑  Food and Drug Administration, Department of Health and Human Services: Code of Federal Regulations 320 Title 21, Volume 5, Revised as of April 1, 2008 CFR 320 21/5, Revised as of April 1, 2008. Accessed 2008-06-15
↑  Health Canada, Drugs and Health Products, Bioavailability and Bioequivalence （页面存档备份，存于） Health Canada, Guidance Documents. Accessed 2008-06-15
1 2  EudraLex – The Rules Governing Medicinal Products in the European Union （页面存档备份，存于） EudraLex. Accessed 2008-06-15
↑  European Medicines Agency （页面存档备份，存于） EMEA. Accessed 2008-06-15
↑  Japan, National Institute for Health Sciences, Division of Drugs Guidances （页面存档备份，存于） Japan, NIHS, Division of Drugs. Accessed 2008-06-15
↑  Page, A; Etherton-Beer, C. . Maturitas. January 2018, 107: 103–109. PMID 29169573. doi:10.1016/j.maturitas.2017.11.001.
↑  Davit, BM; Nwakama PE; Buehler GJ; Conner Dp; Haidar SH; Patel DT; Yang Y; Yu LX; Woodcock J. . Annals of Pharmacotherapy (Submitted manuscript). 2009, 43 (10): 1583–97  [2020-10-21]. PMID 19776300. S2CID 28362065. doi:10.1345/aph.1m141. （原始内容存档于2020-11-12）.
↑  Warren, JB. . Br J Clin Pharmacol. 2013, 75 (1): 7–14. PMC 3555041 . PMID 22574725. doi:10.1111/j.1365-2125.2012.04323.x.
↑  . FDA. October 4, 2007  [2008-06-15]. （原始内容存档于2009-05-31）.
1 2 3  Mossinghoff GJ.  (PDF). Food Drug Law J. 1999, 54 (2): 187–94  [2020-10-21]. PMID 11758572. （原始内容存档 (PDF)于2022-01-10）.
↑  . Approved Drug Products with Therapeutic Equivalence Evaluations 29th Edition. U.S. Food and Drug Administration Center for Drug Evaluation and Research. 2009-06-18  [2009-08-10]. （原始内容存档于2019-04-23）.
↑  . Food and Drug Administration. 26 April 2019  [2020-10-21]. （原始内容存档于2017-09-18）.
↑  Davit;  et al. . Annals of Pharmacotherapy (Submitted manuscript). 2009, 43 (10): 1583–97  [2020-10-21]. PMID 19776300. S2CID 28362065. doi:10.1345/aph.1m141. （原始内容存档于2020-11-12）.
↑  Calo-Fernández, Bruno; Martínez-Hurtado J L. . Pharmaceuticals. 2012-12-12, 5 (12): 1393–1408. PMC 3816668 . PMID 24281342. doi:10.3390/ph5121393.
↑  Approved Drug Products with Therapeutic Equivalence Evaluations, Preface. （页面存档备份，存于） – an explanation of FDA terms and procedures
↑   (PDF). FDA, Center for Drug Evaluation and Research (CDER). June 1998  [August 24, 2009]. （原始内容存档 (PDF)于2017-05-04）.
↑  . FDA, Office of Generic Drugs (OGD). 2008-06-11  [2008-06-16]. （原始内容存档于2009-05-28）.
↑   （页面存档备份，存于）  Bristol-Myers Squibb press release on successful defense of Plavix patent .   [2018-12-20]. （原始内容存档于2007-10-16）.
↑  .   [2017-12-18]. （原始内容存档于2018-03-19）.
↑  Apotex press release on successful challenge of Paxil patent （页面存档备份，存于）
↑  Einer Elhauge & Alex Krueger. . Texas Law Review. 2012-12-21. S2CID 154797144. SSRN 2125456 . doi:10.2139/ssrn.2125456.
↑  Wyatt, Edward. . New York Times. 17 June 2013  [9 May 2015]. （原始内容存档于2021-04-14）.
↑  . FTC. August 2011  [2020-10-21]. （原始内容存档于2017-05-16）.
↑   (PDF). FTC. August 2011  [2020-10-21]. （原始内容存档 (PDF)于2021-03-30）.
↑  .   [2020-10-21]. （原始内容存档于2018-02-11）.
↑  21 C.F.R. Part 10
↑  Carrier, Michael A.; Wander, Daryl.  (PDF). Cardozo Law Review. 2012, 34: 249–293  [2016-09-14]. （原始内容 (PDF)存档于2016-08-03）.
↑  .   [2020-10-21]. （原始内容存档于2010-04-30）.
↑  George T. Haley; Usha C.V. Haley. . Technological Forecasting and Social Change. 2012, 79 (4): 607–619. doi:10.1016/j.techfore.2011.05.012.
↑  Bhosle, Deepak; Sayyed, Asif; Bhagat, Abhijeet; Shaikh, Huzaif; Sheikh, Alimuddin; Bhopale, Vasundhara; Quazi, Zubair. . Annals of International Medical and Dental Research. 20 December 2016, 3 (1). doi:10.21276/aimdr.2017.3.1.PC1 .
↑  Reddy, Prashant. . Scroll.in. April 12, 2017  [2020-12-23]. （原始内容存档于2021-02-02）.
↑  , China Watch (Washington, D.C., United States: Worldwatch Institute), worldwatch.org,   [Jan 3, 2012], （原始内容存档于2018-12-26）
↑  . Cato Institute. 2018-11-15  [2020-04-08]. （原始内容存档于2021-01-27） （英语）.
↑  . 2020-05-25  [2020-10-13]. （原始内容存档于2021-04-29）.
↑  . FiercePharma.   [2020-12-23]. （原始内容存档于2021-02-27） （英语）.
↑  YE, Wanqing. . 贤集网. 2017-11-13. []
↑  .   [2021-03-27]. （原始内容存档于2018-01-05）.
↑  Pereira JA, Holbrook AM, Dolovich L, Goldsmith C, Thabane L, Douketis JD, Crowther MA, Bates SM, Ginsberg JS. . Annals of Pharmacotherapy. 2005, 39 (7–8): 1188–93  [2020-10-21]. PMID 15914517. S2CID 11685122. doi:10.1345/aph.1G003. （原始内容存档于2011-06-16）.
↑  Pereira JA, Holbrook AM, Dolovich L, Goldsmith C, Thabane L, Douketis JD, Crowther M, Bates SM, Ginsberg JS.  (PDF). Can J Clin Pharmacol. 2005, 12 (3): e229–39  [2020-10-21]. PMID 16278495. （原始内容 (PDF)存档于2007-11-29）.
↑  . Pharmaceutical Society of Australia Competency Standards for Pharmacists in Australia 2003. National Prescribing Service Limited (NPS). 2003-07-09  [2010-01-24]. （原始内容存档于2009-10-20）. "Prescribers may disallow brand switching by ticking the relevant box on the PBS prescription form"
↑  苏华; 郭瑞臣. . 中国医院药学杂志. 2022, 42 (14)  [2024-06-18]. doi:10.13286/j.1001-5213.2022.14.21. （原始内容存档于2024-06-18）.
↑  . news.qq.com. 2025-01-18 （中文（中国大陆））.
↑  . www.stcn.com.
↑  . 2012-12-06  [2013-04-20]. （原始内容存档于2020-08-13）.
↑  Healy, Melissa. . Los Angeles Times. 2012-10-05  [2013-04-20]. （原始内容存档于2013-11-09）.
↑  . U.S. Food and Drug Administration. 2012-10-03  [2013-04-20]. （原始内容存档于2019-04-24）.
↑  . FDA. October 2013  [15 June 2015]. （原始内容存档于2019-04-24）.
↑  Strickland, Carol. . The New York Times. 15 October 1989  [2020-10-21]. （原始内容存档于2021-04-14）.
↑  Freudenheim, Milt. . New York Times. 10 September 1989. （原始内容存档于2021-01-26）.
↑  Andrews, Edmund L. . The New York Times. 31 July 1989  [2020-10-21]. （原始内容存档于2020-10-17）.
↑  Bate R, Mathur A, Lever HM, Thakur D, Graedon J, Cooperman T,  et al. . Trends in Pharmacological Sciences. March 2016, 37 (3): 184–191. PMID 26687297. doi:10.1016/j.tips.2015.11.005.
↑  . European Medicines Agency. 2017-03-24  [2020-11-17]. （原始内容存档于2020-10-26）.
1 2  Eban, Katherine. . The New York Times. 11 May 2019  [2019-05-15]. （原始内容存档于2021-05-05）.
↑  . SCOTUS Blog.   [23 May 2017]. （原始内容存档于2021-03-14）.
↑  Supreme Court of the United States 564 PLIVA, Inc. v. Mensing （页面存档备份，存于） U. S. ____ (2011)
↑  Adam Liptak for the New York Times. June 23, 2011 Drug Makers Win Two Supreme Court Decisions （页面存档备份，存于）
↑  Steven Casey for Law360. October 24, 2012 Generic Pharmaceutical Liability: Challenges And Changes （页面存档备份，存于）
↑  Mears, B. . CNN. 2011-06-23  [2013-01-01]. （原始内容存档于2020-09-15）.
1 2  . FiercePharma.   [2019-05-18]. （原始内容存档于2020-10-20） （英语）.
↑  .   [2024-06-03]. （原始内容存档于2024-06-03）.